NASDAQ:STRO Sutro Biopharma (STRO) Stock Price, News & Analysis $1.08 +0.07 (+6.37%) As of 01:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Sutro Biopharma Stock (NASDAQ:STRO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Sutro Biopharma alerts:Sign Up Key Stats Today's Range$1.01▼$1.1850-Day Range$0.68▼$1.0252-Week Range$0.52▼$4.80Volume783,798 shsAverage Volume1.22 million shsMarket Capitalization$91.98 millionP/E RatioN/ADividend YieldN/APrice Target$4.47Consensus RatingHold Company Overview Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California. Read More Sutro Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks77th Percentile Overall ScoreSTRO MarketRank™: Sutro Biopharma scored higher than 77% of companies evaluated by MarketBeat, and ranked 256th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingSutro Biopharma has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 2 buy ratings, 4 hold ratings, and 1 sell rating.Amount of Analyst CoverageSutro Biopharma has only been the subject of 2 research reports in the past 90 days.Read more about Sutro Biopharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Sutro Biopharma are expected to decrease in the coming year, from ($2.92) to ($2.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sutro Biopharma is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sutro Biopharma is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSutro Biopharma has a P/B Ratio of 2.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Sutro Biopharma's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.16% of the outstanding shares of Sutro Biopharma have been sold short.Short Interest Ratio / Days to CoverSutro Biopharma has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Sutro Biopharma has recently increased by 4.44%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSutro Biopharma does not currently pay a dividend.Dividend GrowthSutro Biopharma does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.70 Percentage of Shares Shorted4.16% of the outstanding shares of Sutro Biopharma have been sold short.Short Interest Ratio / Days to CoverSutro Biopharma has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Sutro Biopharma has recently increased by 4.44%, indicating that investor sentiment is decreasing. News and Social Media3.0 / 5News Sentiment1.37 News SentimentSutro Biopharma has a news sentiment score of 1.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Sutro Biopharma this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for STRO on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Sutro Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sutro Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.60% of the stock of Sutro Biopharma is held by insiders.Percentage Held by Institutions96.99% of the stock of Sutro Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sutro Biopharma's insider trading history. Receive STRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. STRO Stock News HeadlinesVaxcyte Advances VAX-31 Infant Phase 2 Study with New Optimized Dose Aimed at Enhancing Immune Response Against Invasive Pneumococcal DiseaseSeptember 3 at 7:50 AM | quiverquant.comQSutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Rating of "Hold" from AnalystsAugust 30, 2025 | americanbankingnews.comWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.September 5 at 2:00 AM | Banyan Hill Publishing (Ad)Sutro Biopharma’s STRO-002: A Promising Phase 1 Trial Update in Ovarian and Endometrial CancersAugust 20, 2025 | msn.comSutro Biopharma (STRO) Gets a Buy from Truist FinancialAugust 14, 2025 | theglobeandmail.comSutro Biopharma price target lowered to $3 from $4 at Wells FargoAugust 12, 2025 | msn.comAnalysts Offer Insights on Healthcare Companies: Sutro Biopharma (STRO) and Relay Therapeutics (RLAY)August 9, 2025 | theglobeandmail.comSutro Biopharma, Inc.: Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business HighlightsAugust 8, 2025 | finanznachrichten.deSee More Headlines STRO Stock Analysis - Frequently Asked Questions How have STRO shares performed this year? Sutro Biopharma's stock was trading at $1.84 at the beginning of 2025. Since then, STRO stock has decreased by 38.3% and is now trading at $1.1350. How were Sutro Biopharma's earnings last quarter? Sutro Biopharma, Inc. (NASDAQ:STRO) issued its earnings results on Thursday, August, 7th. The company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.39) by $0.25. The company had revenue of $63.74 million for the quarter, compared to analyst estimates of $14.55 million. Sutro Biopharma had a negative net margin of 201.32% and a negative trailing twelve-month return on equity of 852.70%. When did Sutro Biopharma IPO? Sutro Biopharma (STRO) raised $75 million in an initial public offering on Thursday, September 27th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Sutro Biopharma's major shareholders? Sutro Biopharma's top institutional shareholders include Velan Capital Investment Management LP (3.61%), Acadian Asset Management LLC (3.60%), Geode Capital Management LLC (0.97%) and Jane Street Group LLC (0.81%). Insiders that own company stock include Nicki Vasquez and Brunilda Shtylla. View institutional ownership trends. How do I buy shares of Sutro Biopharma? Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sutro Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sutro Biopharma investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Moderna (MRNA) and Home Depot (HD). Company Calendar Last Earnings8/07/2025Today9/05/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:STRO CIK1382101 Webwww.sutrobio.com Phone(650) 392-8412FaxN/AEmployees240Year FoundedN/APrice Target and Rating Average Price Target for Sutro Biopharma$4.47 High Price Target$17.00 Low Price Target$0.80 Potential Upside/Downside+315.5%Consensus RatingHold Rating Score (0-4)2.14 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($2.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$227.46 million Net Margins-201.32% Pretax Margin-199.07% Return on Equity-852.70% Return on Assets-58.67% Debt Debt-to-Equity RatioN/A Current Ratio3.12 Quick Ratio3.12 Sales & Book Value Annual Sales$62.04 million Price / Sales1.47 Cash FlowN/A Price / Cash FlowN/A Book Value$0.54 per share Price / Book1.99Miscellaneous Outstanding Shares84,770,000Free Float81,722,000Market Cap$91.13 million OptionableOptionable Beta1.57 Social Links 10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:STRO) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sutro Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sutro Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.